PMID: 11926715Apr 3, 2002Paper

Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects

The Journal of Clinical Psychiatry
Sidney H KennedyGlen B Baker

Abstract

This study was designed to evaluate the effect of combining bupropion sustained release (SR) with venlafaxine, paroxetine, or fluoxetine in patients who reported unacceptable sexual dysfunction when treated with monotherapy with the latter 3 agents. Following a minimum of 6 weeks of antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) or venlafaxine (a serotonin-norepinephrine reuptake inhibitor), eligible subjects received a further 8 weeks of monitored combination therapy with bupropion SR at a dose of 150 mg/day with no alterations to index antidepressant dosing. There was a clinically significant benefit in 14 (78%) of 18 partial responders or nonresponders, and 33% (N = 6) achieved a full response (chi2= 8.06, df = 2, p = .017). Sexual dysfunction, particularly a decrease in orgasmic delay, was also significantly improved with combination therapy (men: paired t = -2.1, df = 6, p = .08; women: paired t = -3.0, df = 7, p = .02). Plasma monitoring of drugs and their metabolites revealed a statistically significant increase in venlafaxine levels (F = 6.89, df = 4,24; p = .001) accompanied by a decrease in O-desmethylvenlafaxine (F = 14.26; df = 4,24; p < .0005) during combined treatment with bupropion ...Continue Reading

Citations

Nov 13, 2002·Pharmacoepidemiology and Drug Safety
Jun 19, 2012·Current Psychiatry Reports·Brett A EnglishStanford Jhee
Jun 9, 2004·Journal of Affective Disorders·Gabriel RubioCecilio Alamo
Oct 17, 2013·Pharmacology, Biochemistry, and Behavior·Elisabeth Y BijlsmaRonald S Oosting
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ali Saffet GonulSimavi Vahip
Apr 15, 2008·International Clinical Psychopharmacology·Madhukar H TrivediMichael J Detke
Mar 18, 2005·Seminars in Dialysis·Eliana TossaniMaurizio Fava
May 11, 2005·Psychosomatics·Jose de LeonKelly L Cozza
Dec 24, 2013·Addiction Science & Clinical Practice·Karine Giasson-Gariépy, Didier Jutras-Aswad
Mar 25, 2008·Therapeutics and Clinical Risk Management·Kevin Kjernisted, Diane McIntosh
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Jul 12, 2011·Clinical Pharmacokinetics·Michel TodBruno Charpiat
Dec 17, 2011·CNS Drugs·Edoardo SpinaFilippo Caraci
Mar 30, 2005·Expert Opinion on Drug Safety·Sunke HimpelAribert Rothenberger
Jul 9, 2011·Depression Research and Treatment·Luis M Martín-LópezJulio Vallejo
Sep 17, 2005·Biological Psychiatry·Sidney ZisookCarol B Rockett
Apr 8, 2016·Scientific Reports·Fangxi ZhangHongbo Wang
Feb 22, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jillissa C Molnari, Alan L Myers
Jun 4, 2016·The Journal of Pharmacology and Experimental Therapeutics·Andrea R MastersZeruesenay Desta
Sep 20, 2005·Journal of Affective Disorders·Seetal DoddMichael Berk
Jun 9, 2005·The Annals of Pharmacotherapy·Stephen M SetterDanial E Baker
Jan 18, 2005·Revista do Hospital das Clínicas·Márcio BernikPaula Villela Nunes
Oct 13, 2009·Journal of Psychiatric Practice·Jonathan W StewartFrederic M Quitkin
Sep 2, 2004·Pharmacotherapy·Cynthia A CarnesSubha V Raman
May 7, 2005·Journal of Clinical Psychopharmacology·Michael KotlyarDavid E Adson
Mar 1, 2008·Journal of Psychopharmacology·K Demyttenaere, L Jaspers
Sep 7, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Ranjeet Prasad DashNuggehally R Srinivas
May 1, 2004·Journal of Clinical Psychopharmacology·Robert Taylor SegravesJill Warnock
Mar 11, 2006·Depression and Anxiety·George I PapakostasMaurizio Fava
Jul 16, 2010·Journal of Clinical Psychopharmacology·Georgios PaslakisMichael Deuschle
Nov 17, 2009·Journal of Clinical Psychopharmacology·Wan-Chen ChengTzung-Jeng Hwang
Nov 26, 2005·Acta Psychiatrica Scandinavica. Supplementum·J E RojoJ M de Pedro
Jul 13, 2006·Expert Review of Neurotherapeutics·Felicity NgMichael Berk
Sep 9, 2006·CNS Drug Reviews·Phil SkolnickArnold Lippa
Apr 19, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Melinda J ReeseDonavon J McConn
Aug 20, 2019·Therapeutic Drug Monitoring·Ramon R ContrucciLaura Hondebrink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Related Papers

The Journal of Clinical Psychiatry
Anita H ClaytonAlan Metz
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
S Devarajan, S M Dursun
© 2022 Meta ULC. All rights reserved